Expertise in
2
conditions

Andreas Trojan

Hirslanden Klinik Im Park, 
Zuerich (kreis 7) / Hirslanden, ZH, CH 
Expertise in
2
conditions
Hirslanden Klinik Im Park, 
Zuerich (kreis 7) / Hirslanden, ZH, CH 

Overview

Andreas Trojan practices practicing medicine in Zuerich (kreis 7) / Hirslanden, Switzerland.

Mr. Trojan is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Febrile Neutropenia, Plasmacytoma, and Anemia.

He is actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Hirslanden Klinik Im Park, Zuerich (kreis 7) / Hirslanden, ZH, Switzerland
Other Locations
Clinics In The Park, Zurich, ZH, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Drug
Study Drug: Denosumab
Study Phase: Phase 3
Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer During Chemotherapy in Combination With HER2-targeted Therapy (Including Tyrosine Kinase Inhibitors [TKI]) or an Antibody-drug Conjugate Therapy: a Multicenter Randomized Controlled Trial.
Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer During Chemotherapy in Combination With HER2-targeted Therapy (Including Tyrosine Kinase Inhibitors [TKI]) or an Antibody-drug Conjugate Therapy: a Multicenter Randomized Controlled Trial.
Enrollment Status: Terminated
Publish Date: September 22, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Stratified, Multicenter Phase II Trial of Transdermal CR1447 (4-OH-testosterone) in Endocrine Responsive-HER2 Negative and Triple Negative-androgen Receptor Positive Metastatic or Locally Advanced Breast Cancer
A Stratified, Multicenter Phase II Trial of Transdermal CR1447 (4-OH-testosterone) in Endocrine Responsive-HER2 Negative and Triple Negative-androgen Receptor Positive Metastatic or Locally Advanced Breast Cancer
Enrollment Status: Terminated
Publish Date: June 27, 2023
Intervention Type: Drug
Study Drug: CR1447
Study Phase: Phase 2
Eribulin as 1st Line Treatment in Elderly Patients (≥ 70 Years) With Advanced Breast Cancer: a Multicenter Phase II Trial
Eribulin as 1st Line Treatment in Elderly Patients (≥ 70 Years) With Advanced Breast Cancer: a Multicenter Phase II Trial
Enrollment Status: Terminated
Publish Date: September 29, 2021
Intervention Type: Drug
Study Drug: Eribulin Mesilate
Study Phase: Phase 2
Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer - A Multicenter Single Arm Phase II Trial
Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer - A Multicenter Single Arm Phase II Trial
Enrollment Status: Terminated
Publish Date: September 29, 2021
Intervention Type: Drug
Study Drug: anti-EGFR-IL-dox
Study Phase: Phase 2
View 4 Less Clinical Trials

43 Total Publications

Revisiting the OGIPRO Trial: Dynamic Electronic Patient-Reported Outcomes Compared with EQ-5D-5L in HER2-Positive Breast Cancer.
Revisiting the OGIPRO Trial: Dynamic Electronic Patient-Reported Outcomes Compared with EQ-5D-5L in HER2-Positive Breast Cancer.
Journal: Cancers
Published: January 27, 2026

Frequently Asked Questions about Andreas Trojan

Is Andreas Trojan a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Andreas Trojan is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Andreas Trojan participate in research or clinical trials?

Yes. Andreas Trojan has published 43 articles and abstracts on conditions like Breast Cancer. You can view a list of Andreas Trojan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Trojan's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile